CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

83 papers

Active filtersClassification:Supporting

Showing 13-24 of total 83 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedSupporting evidence

B-cell targeting strategies for the treatment of multiple sclerosis: from non-cellular therapies to CAR-engineered cell therapies.

Salomova N; Khachatryan LG; Amonov A; Normatov M; Khalmatova N; Rashidov A; Babamuratov B

Jan 1, 2026Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

2026PubMedSupporting evidence

Transduction efficiency in clinical CAR T cell products: A retrospective study at a single center.

Shao L; Prochazkova M; Cai Y; Lee Han K; Martin K; Shi R; Yang R; Ma J; Zheng Y; Garces P; Frodigh SE; Pham V; Zhang N; Somerville RP; Stroncek DF; Jin P

Jan 1, 2026Molecular therapy. Advances

2026PubMedSupporting evidence

Leukemic Stem Cell-Targeted Liposomal Nanoimmunotherapy Reverses Immune Evasion and Inhibits Fusion Oncoprotein-Driven Acute Myeloid Leukemia by Silencing B-Cell Lymphoma 2.

Ayoub M; Ghosh D; Sahu VK; Biswal L; Malhotra P; Karmakar S; Choudhury SR

Jan 1, 2026Acta biomaterialia

2026PubMedSupporting evidence

Single-cell tracking reveals tumor-reactive T cell plasticity during melanoma TIL therapy.

Sandholzer MT; Serger C; Liner AG; Uzun S; König D; Thut H; Ritschard R; Fürst JD; Zingg A; Mantuano NR; Kasenda B; Glatz K; Kappos EA; Matter M; Holbro A; Stenner F; Passweg J; Khanna N; Jeker L; Binder M; Zippelius A; Läubli H

Jan 1, 2026Cell reports. Medicine

2026PubMedSupporting evidence

A bio-orthogonally engineered probiotic-T cell chimera amplifies adoptive cell therapy through spatial DC-T cell immune licensing.

Shen J; Chu Y; Wang Y; Chen X; Ke Y; Huo D; Zhu J; Hong S; Qin S; Liu B; Liu Q

Jan 1, 2026Science bulletin

2026PubMedSupporting evidence

T-cell lymphoma following chimeric antigen receptor-T therapy: a cause for concern?

Stella F; Fraietta JA; Schuster SJ; Ruella M

Jan 1, 2026Haematologica

2026PubMedSupporting evidence

Chimeric antigen receptor T-cell therapy in autoimmune rheumatic diseases: defining the reset-opportunity window.

Gwóźdź-Broczkowska A

Jan 1, 2026Clinical and experimental rheumatology

2026PubMedSupporting evidence

Structural Foundation of CTLA-4 antibodies: Emerging Platforms for Next-generation Cancer Immunotherapy.

Leta EM; Syed S; Binegde GN; Gu D; Xiong J; Wang F

Jan 1, 2026International immunopharmacology

2026PubMedSupporting evidence

Structural Foundation of CTLA-4 antibodies: Emerging Platforms for Next-generation Cancer Immunotherapy.

Leta EM; Syed S; Binegde GN; Gu D; Xiong J; Wang F

Jan 1, 2026International immunopharmacology

2026PubMedSupporting evidence

Thymine-functionalized bPEI nanocomplexes for synergistic STING activation and PD-L1 silencing to potentiate cancer immunotherapy.

Chen L; Song MH; Jin M; Jin H; Gong L; Feng J; Hao Y; Shao H; Gong X; Gao Z; Yang Q; Huang W

Jan 1, 2026Journal of controlled release : official journal of the Controlled Release Society

2026PubMedSupporting evidence

Thymine-functionalized bPEI nanocomplexes for synergistic STING activation and PD-L1 silencing to potentiate cancer immunotherapy.

Chen L; Song MH; Jin M; Jin H; Gong L; Feng J; Hao Y; Shao H; Gong X; Gao Z; Yang Q; Huang W

Jan 1, 2026Journal of controlled release : official journal of the Controlled Release Society

2026PubMedSupporting evidence

Comprehensive microRNA profiling coupled with function-based feature selection reveals a biomarker panel for predicting CAR-T cell exhaustion.

Nakamura N; Seo H; Hamada R; Kaneko H; Kagoya Y; Ohta S

Jan 1, 2026Biochemical and biophysical research communications